Promiscuous targeting of bromodomains by Bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET inhibitors and their significant activity in diverse tumor models has rapidly translated into clinical studies and has motivated drug development efforts targeting non-BET BRDs. How...
Main Authors: | Picaud, S, Leonards, K, Lambert, J, Dovey, O, Wells, C, Fedorov, O, Monteiro, O, Fujisawa, T, Wang, C, Lingard, H, Tallant, C, Nikbin, N, Guetzoyan, L, Ingham, R, Ley, S, Brennan, P, Muller, S, Samsonova, A, Gingras, A, Schwaller, J, Vassiliou, G, Knapp, S, Filippakopoulos, P |
---|---|
Format: | Journal article |
Published: |
American Association for the Advancement of Science
2016
|
Similar Items
-
Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012) -
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
by: Picaud, S, et al.
Published: (2013) -
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
by: Picaud, S, et al.
Published: (2013) -
Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013) -
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)